Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer’s

References

• Alzheimer’s Association. 2023. Alzheimer’s disease facts and figures. Alzheimer’s Dementia. 2023;19:1598–1695. doi: 10.1002/alz.13016
   PubMedGoogle Scholar
• Tahami Monfared AA, Byrnes MJ, White LA, et al. The humanistic and economic burden of Alzheimer’s disease. Neurol Ther. 2022; 11(2):525–551. doi: 10.1007/s40120-022-00335-x
   Web of Science ®Google Scholar
• Yiannopoulou KG, Papageorgiou SG Current and future treatments in Alzheimer disease: an update. J Cent Nerv Syst Dis. 2020 Feb 29;12:1179573520907397. doi: 10.1177/1179573520907397 PMID: 32165850; PMCID: PMC7050025
   Web of Science ®Google Scholar
• Cheong SL, Tiew JK, Fong YH, et al. Current Pharmacotherapy and multi-target approaches for Alzheimer’s disease. Pharmaceuticals (Basel). 2022 Dec 14;15:(12) 1560. doi: 10.3390/ph15121560 PMID: 36559010; PMCID: PMC9781592
   PubMedGoogle Scholar
• Guo T, Zhang D, Zeng Y, et al. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease. Mol Neurodegener. 2020;15(1):40. doi: 10.1186/s13024-020-00391-7
   PubMed Web of Science ®Google Scholar
• McDade E, Bateman RJ. Stop Alzheimer’s before it starts. Nature. 2017;547(7662):153–155. doi: 10.1038/547153a
   PubMed Web of Science ®Google Scholar
• Tariq S, Barber PA. Dementia risk and prevention by targeting modifiable vascular risk factors. J Neurochem. 2018;144(5):565–581. doi: 10.1111/jnc.14132
   PubMed Web of Science ®Google Scholar
• Cuyvers E, Sleegers K. Genetic variations underlying Alzheimer’s disease: evidence from genome-wide association studies and beyond. Lancet Neurol. 2016;15(8):857–868. doi: 10.1016/S1474-4422(16)00127-7
   PubMed Web of Science ®Google Scholar
• Swerdlow RH. Pathogenesis of Alzheimer’s disease. Clin Interv Aging. 2007;2:347–359. PMID: 18044185; PMCID: PMC2685260 3
   PubMed Web of Science ®Google Scholar
• Tiwari S, Atluri V, Kaushik A, et al. Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine. 2019 Jul 19;14:5541–5554. doi: 10.2147/IJN.S200490 PMID: 31410002; PMCID: PMC6650620
   PubMed Web of Science ®Google Scholar
• Gallardo G, Holtzman DM. Amyloid-β and tau at the crossroads of Alzheimer’s disease. Adv Exp Med Biol. 2019;1184:187–203. doi: 10.1007/978-981-32-9358-8_16 PMID: 32096039
   PubMed Web of Science ®Google Scholar
• Dhillon S. Aducanumab: first approval. Drugs. 2021 Aug;81:(12)1437–1443. doi: 10.1007/s40265-021-01569-z Erratum in: Drugs. 2021 Sep;81:1701. PMID: 34324167
   PubMed Web of Science ®Google Scholar
• Shi M, Chu F, Zhu F, et al. Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of alzheimer’s disease: a focus on aducanumab and lecanemab. Front Aging Neurosci. 2022 Apr 12;14:870517. doi: 10.3389/fnagi.2022.870517 PMID: 35493943; PMCID: PMC9039457
   PubMed Web of Science ®Google Scholar
• Hampel H, Mesulam MM, Cuello AC, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain. 2018 Jul 1;141:1917–1933. doi: 10.1093/brain/awy132 PMID: 29850777; PMCID: PMC6022632 7
   PubMedGoogle Scholar
• Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement. 2021 Apr;17:696–701. doi: 10.1002/alz.12213 Epub 2020 Nov 1. PMID: 33135381
   PubMed Web of Science ®Google Scholar
• Alexander GC, Emerson S, Kesselheim AS. Evaluation of aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA. 2021;325(17):1717–1718. doi: 10.1001/jama.2021.3854
   PubMed Web of Science ®Google Scholar
• Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537(7618):50–56. doi: 10.1038/nature19323
   PubMed Web of Science ®Google Scholar
• Salloway S, Chalkias S, Barkhof F, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early alzheimer disease. JAMA Neurol. 2022 Jan 1;79:13–21. doi: 10.1001/jamaneurol.2021.4161 PMID: 34807243; PMCID: PMC8609465 1
   PubMed Web of Science ®Google Scholar
• Biogen. c1978-2024. Biogen to realign resources for alzheimer’s disease franchise. Cambridge (MS): Biogen Inc.; [cited 2024 Jan 31]. Available from: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
   Google Scholar
• van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023 Jan 5;388:9–21. doi: 10.1056/NEJMoa2212948 Epub 2022 Nov 29. PMID: 36449413
   PubMedGoogle Scholar
• Iwatsubo T, Saido TC, Mann DM, et al. Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. Am J Pathol. 1996 Dec;149(6):1823–1830. PMID: 8952519; PMCID: PMC1865366
   PubMed Web of Science ®Google Scholar
• Kuo YM, Emmerling MR, Woods AS, et al. Isolation, chemical characterization, and quantitation of a beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem Biophys Res Commun. 1997 Aug 8;237(1):188–191. doi: 10.1006/bbrc.1997.7083 PMID: 9266855
   PubMed Web of Science ®Google Scholar
• Saido TC, Iwatsubo T, Mann DM, et al. Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques. Neuron. 1995 Feb;14(2):457–466. doi: 10.1016/0896-6273(95)90301-1 PMID: 7857653
   PubMed Web of Science ®Google Scholar
• Demattos RB, Lu J, Tang Y, et al. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer’s disease mice. Neuron. 2012 Dec 6;76:908–920. doi: 10.1016/j.neuron.2012.10.029 PMID: 23217740
   PubMed Web of Science ®Google Scholar
• Lowe SL, Duggan Evans C, Shcherbinin S, et al. Donanemab (LY3002813) Phase 1b Study in Alzheimer’s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging. J Prev Alzheimers Dis. 2021;8:414–424. doi: 10.14283/jpad.2021.56 PMID: 34585215
   PubMed Web of Science ®Google Scholar
• Lowe SL, Willis BA, Hawdon A, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer’s disease. Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12112. doi: 10.1002/trc2.12112 PMID: 33614890; PMCID : PMC7882532
   PubMedGoogle Scholar
• Irizarry MC, Sims JR, Lowe SL, et al. (2016). O4-08-06: safety, pharmacokinetics (pk), and florbetapir f-18 positron emission tomography (pet) after multiple dose administration of ly3002813, a β-amyloid plaque-specific antibody, in Alzheimer’s disease (Ad), In Alzheimer’s Dementia, 12:7S_Part_7. 352–353. doi: 10.1016/j.jalz.2016.06.665
   Google Scholar
• Keizer RJ, Huitema AD, Schellens JH, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clini Pharma. 2010 Aug;49(8):493–507. doi: 10.2165/11531280-000000000-00000 PMID: 20608753
   Google Scholar
• Gueorguieva I, Willis BA, Chua L, et al. Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer’s disease. Clin Pharmacol Ther. 2023 Jun;113(6):1258–1267. doi: 10.1002/cpt.2875 Epub 2023 Mar 9. PMID: 36805552
   PubMed Web of Science ®Google Scholar
• Rashad A, Rasool A, Shaheryar M, et al. Donanemab for Alzheimer’s Disease: a systematic review of clinical trials. Healthcare (Basel). 2022 Dec 22;11(1):32. doi: 10.3390/healthcare11010032 PMID: 36611492; PMCID: PMC9818878
   PubMedGoogle Scholar
• Shcherbinin S, Evans CD, Lu M, et al. Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022 Oct 1;79(10):1015–1024. doi: 10.1001/jamaneurol.2022.2793 PMID: 36094645; PMCID: PMC9468959.
   PubMed Web of Science ®Google Scholar
• Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in Early Alzheimer’s Disease. N Engl J Med. 2021 May 6;384:1691–1704. doi: 10.1056/NEJMoa2100708 Epub 2021 Mar 13. PMID: 33720637
   PubMed Web of Science ®Google Scholar
• Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512–527. doi:10.1001/jama.2023.13239
   PubMed Web of Science ®Google Scholar
• Alzforum [Internet]. [ updated 2024 Jan 30; cited 2024 Jan 24]. Available from: https://www.alzforum.org/therapeutics/donanemab
   Google Scholar
• Salloway S, Lee E, Papka M, et al. TRAILBLAZER-ALZ 4: Topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer’s disease. BJPsych Open. 2023 Jul 7;9:S67. doi: 10.1192/bjo.2023.227 PMCID: PMC10345621
   Web of Science ®Google Scholar
• Agarwal A, Gupta V, Brahmbhatt P, et al. Amyloid-related imaging abnormalities in Alzheimer disease treated with anti–Amyloid-β therapy. Radiographics. 2023 Sep;43(9):e230009. doi: 10.1148/rg.230009 PMID: 37651273; PMCID: PMC10715974
   PubMed Web of Science ®Google Scholar
• Sperling RA, Cr Jack Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s association research roundtable workgroup. Alzheimer’s Dementia. 2011 Jul;7(4):367–385. doi: 10.1016/j.jalz.2011.05.2351 PMID: 21784348; PMCID: PMC3693547
   PubMed Web of Science ®Google Scholar
• Klein EG, Schroeder K, Wessels AM, et al. How donanemab data address the coverage with evidence development questions. Alzheimers Dement. 2024 Apr;20(4):3127–3140. doi: 10.1002/alz.13700 Epub 2024 Feb 7. PMID: 38323738; PMCID: PMC11032520
   PubMed Web of Science ®Google Scholar
• Barrett JE, Page CP, Michel MC Concepts and principles of pharmacology: 100 years of the handbook of experimental pharmacology. Cham: Springer; 2020
   Google Scholar
• Shih T, Lee K, Grogan T, et al. Infliximab in hidradenitis suppurativa: a systematic review and meta‐analysis. Dermatologic Therapy. 2022;35(9) doi: 10.1111/dth.15691
   Web of Science ®Google Scholar
• Bylsma LC, Dean R, Lowe K, et al. The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: a systematic literature review and meta‐analysis of patient and study characteristics. Cancer Med. 2019;8(12):5800–5809. doi: 10.1002/cam4.2413
   PubMed Web of Science ®Google Scholar
• Rombouts MD, Swart EL, Van Den Eertwegh AJM, et al. Systematic Review on Infusion Reactions to and Infusion rate of monoclonal antibodies used in cancer treatment. Anticancer Res. 2020;40(3):1201–1218. doi: 10.21873/anticanres.14062
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab. Eli Lilly and Company. [ Updated 2023 Jan 19; cited 2023 Jan 19]. Available from: https://investor.lilly.com/news-releases/news-release-details/us-food-and-drug-administration-issues-complete-response-0
   Google Scholar
• Steenhuysen J, Silver A. Exclusive: Eisai expects 1,500 alzheimer’s patients in China launch, sees ‘huge’ growth. Reuters [Internet]. [cited 2024 Feb 5]. Available from: https://www.reuters.com/business/healthcare-pharmaceuticals/eisai-expects-1500-alzheimers-patients-china-launch-sees-huge-growth-2024-02-04/
   Google Scholar
• U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab. Eli Lilly and Company. [cited 2024 Mar 8]. Available from: https://investor.lilly.com/news-releases/news-release-details/us-food-and-drug-administration-convene-advisory-committee
   Google Scholar